Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate
multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform
trial design.
Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in
participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.
Phase:
Phase 2
Details
Lead Sponsor:
U.S. Army Medical Research and Development Command